Gentian Violet Inhibits Cell Proliferation through Induction of Apoptosis in Ovarian Cancer Cells

被引：4

作者：

Choi, Min Sung ^{[1
]}

Kim, Ji Hyeon ^{[2
]}

Lee, Chae Yeon ^{[2
]}

Lee, Yul Min ^{[1
]}

Lee, Sukmook ^{[1
,2
,3
]}

Chang, Ha Kyun ^{[4
]}

Kim, Hyun Jung ^{[1
,2
,3
]}

Heo, Kyun ^{[1
,2
,3
]}

机构：

[1] Kookmin Univ, Dept Biopharmaceut Chem, Seoul 02707, South Korea

[2] Kookmin Univ, Sch Appl Chem, Seoul 02707, South Korea

[3] Kookmin Univ, Antibody Res Inst, Seoul 02707, South Korea

[4] Korea Univ, Ansan Hosp, Coll Med, Dept Obstet & Gynecol, Ansan 15855, South Korea

来源：

BIOMEDICINES | 2023年 / 11卷 / 06期

基金：

新加坡国家研究基金会;

关键词：

gentian violet; ovarian cancer; apoptosis; TUMOR-GROWTH; SUPPRESSION; FAMILY; P53;

D O I：

10.3390/biomedicines11061657

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Gentian violet (GV) is known to have antibacterial and antifungal effects, but recent studies have demonstrated its inhibitory effects on the growth of several types of cancer cells. Here, we investigated the anticancer efficacy of GV in ovarian cancer cells. GV significantly reduced the proliferation of OVCAR8, SKOV3, and A2780 cells. Results of transferase dUTP nick and labeling (TUNEL) assay and Western blot assay indicated that the inhibitory effect of GV on ovarian cancer cells was due to the induction of apoptosis. Moreover, GV significantly increased reactive oxygen species (ROS) and upregulated the expression of p53, PUMA, BAX, and p21, critical components for apoptosis induction, in ovarian cancer cells. Our results suggest that GV is a novel antiproliferative agent and is worthy of exploration as a potential therapeutic agent for ovarian cancer.

引用

页数：10

共 31 条

[1] Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes [J].

Beaufort, Corine M. ;

Helmijr, Jean C. A. ;

Piskorz, Anna M. ;

Hoogstraat, Marlous ;

Ruigrok-Ritstier, Kirsten ;

Besselink, Nicolle ;

Murtaza, Muhammed ;

van IJcken, Wilfred F. J. ;

Heine, Anouk A. J. ;

Smid, Marcel ;

Koudijs, Marco J. ;

Brenton, James D. ;

Berns, Els M. J. J. ;

Helleman, Jozien .

PLOS ONE, 2014, 9 (09)

[2] Nox family NADPH oxidases: Molecular mechanisms of activation [J].

Brandes, Ralf P. ;

Weissmann, Norbert ;

Schroeder, Katrin .

FREE RADICAL BIOLOGY AND MEDICINE, 2014, 76 :208-226

[3]

Chen JY, 2022, AM J CANCER RES, V12, P3357

[4] Gentian violet induces wtp53 transactivation in cancer cells [J].

Garufi, Alessia ;

D'Orazi, Valerio ;

Arbiser, Jack L. ;

D'Orazi, Gabriella .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (04) :1084-1090

[5] Drug repurposing for cancer therapy, easier said than done [J].

Gonzalez-Fierro, Aurora ;

Duenas-Gonzalez, Alfonso .

SEMINARS IN CANCER BIOLOGY, 2021, 68 :123-131

[6] Ovarian cancer [J].

Hennessy, Bryan T. ;

Coleman, Robert L. ;

Markman, Maurie .

LANCET, 2009, 374 (9698) :1371-1382

[7] The NADPH Oxidase Family and its Inhibitors [J].

Kleniewska, Paulina ;

Piechota, Aleksandra ;

Skibska, Beata ;

Goraca, Anna .

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2012, 60 (04) :277-294

[8] Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment [J].

Kurnit, Katherine C. ;

Fleming, Gini F. ;

Lengyel, Ernst .

OBSTETRICS AND GYNECOLOGY, 2021, 137 (01) :108-121

[9] Gentian Violet: a 19th century drug re-emerges in the 21st century [J].

Maley, Alexander M. ;

Arbiser, Jack L. .

EXPERIMENTAL DERMATOLOGY, 2013, 22 (12) :775-780

[10] The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects [J].

Mao, Chih-Lin ;

Seow, Kok-Min ;

Chen, Kuo-Hu .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)

← 1 2 3 4 →